- Brain Tumors
- Support Services
- Take Action
- About Us
The global COVID-19 pandemic disrupted nearly every facet of life in 2020, and brain cancer research, particularly clinical trials, was not spared from its impacts. As is often the case, though, with disruption comes the opportunity to innovate. Convening key stakeholders across the brain tumor community, the National Brain Tumor Society (NBTS) has taken stock of these opportunities and how they ultimately can benefit brain tumor patients and caregivers.
Clinical trials are vital to the development, evaluation, and approval of new treatments that can improve the lives of brain tumor patients. The trials themselves can often also offer the best treatment options available for patients diagnosed with aggressive malignant tumors for which there are few current standards of care. Even so, only a small percentage of patients diagnosed with malignant brain tumors end up taking part in a clinical trial. NBTS and others in the neuro-oncology field are committed to closing this gap and have formed a working group dedicated to connecting more patients with clinical trials that are right for them.
A few years ago, NBTS showed us the problem with the low accrual in clinical trials. This led to a joint effort… trying to figure out what we can do to improve trial accrual, looking at things like telemedicine. All of that seemed really hard at that time… and then COVID happened, and overnight the things that were difficult suddenly became routine. This disruption has allowed us to understand what works and what doesn’t work. Many of the things that we routinely did in the past are probably not that necessary. This is an opportunity for us to reimagine how we can do trials, to do things more efficiently so that we can help our patients better.Attribution: Dr. Patrick Wen of Dana-Farber Cancer Institute, and Chair of NBTS’s Medical Advisory Board
On July 24, 2020, NBTS hosted a virtual Research Roundtable to determine what changes brought on by COVID-19 may actually benefit brain tumor clinical trials now and in the future.
“We brought together experts from neuro-oncology clinical research, biopharmaceutical and medical technology companies, the Food and Drug Administration, National Institutes of Health, and importantly patients and patient advocates to delve into the details of barriers and opportunities to leverage the virtual environment to keep clinical trials going and improve them for patients and the family members and friends who support them,” said NBTS CEO David Arons.
The meeting, led by Drs. Eudocia Lee and Wen from Dana Farber Cancer Institute, resulted in a new paper in the journal Neuro-Oncology that chronicles key takeaways and offers actionable insights and next steps that the brain tumor field can use to improve clinical trials in the long term.
As the pandemic took hold across the country, hospitals and cancer centers quickly shifted to virtual appointments and made adjustments to ensure the safety of patients and clinical staff during routine care visits and clinical trials. Some procedures such as basic lab work (e.g., blood tests), and even some medical imaging appointments that otherwise would have been conducted at a main trial site were moved to local settings in patients’ own communities. And, when permitted, FDA-approved study drugs were shipped to local physicians or pharmacies for patients.
A number of policies were put in place by government agencies like the FDA, NCI, and the U.S. Centers for Medicare & Medicaid Services (CMS) to offer more flexibility to patients and those conducting clinical trials. These included waivers that permitted easier access to telemedicine, as well as guidance from the FDA and NCI on how to conduct health care visits and clinical trials in this new world of “decentralized” (trials using telemedicine, mobile or local health care provider, and/or mobile technology) or “hybrid” (combination of traditional and decentralized) trials, without compromising patient safety or the integrity of the data needed to evaluate potential new treatments.
As a result, rapid adoption of telehealth took hold, with some cancer centers reporting that almost two-thirds of follow-up care was conducted virtually.
Decentralized and hybrid trials were found to offer a potentially more patient-friendly setting and minimize some potential barriers to participation in trials. The main advantages to patients were found to include:
The ability to shift trials to a decentralized or hybrid model, making use of new technology and telehealth, would increase the ability for more patients from diverse backgrounds, different financial means, and in more rural areas to have more options to access cutting-edge trials, regardless of location.
While COVID-19 has highlighted areas that can be improved to help make clinical trials more accessible for a greater number of patients, the NBTS roundtable identified a number of barriers that require continued attention. These include issues related to:
Finally, it was noted that although telehealth offers tremendous opportunities to make life easier for patients, it does also carry the risk of potentially exacerbating existing disparities in treatment. For example, telemedicine is often less accessible to racial and ethnic minorities, patients with limited English proficiency, those with lower incomes, and those who are elderly or have physical or cognitive deficits. Patients with low digital literacy who live alone and cannot operate the technology and resources needed for telemedicine without assistance are also at a disadvantage. These disparities can be compounded by limited access to broadband or high-speed internet and related technologies. All actions to improve access to clinical trials must ensure there are no unintended consequences that harm already disadvantaged groups.
To advance a vision of decentralized or hybrid trials becoming the “new normal” for brain tumor patients, the group determined action items for researchers, clinicians, and patient advocacy organizations to take in order to combat these challenges.
Policy issues that impact the larger health care system
Issues such as cross-state medical licensing, cross-state distribution of drugs, and continued health insurance reimbursement for telemedicine are problems that many across the health and medical landscape are interested in solving. As a patient advocacy organization, NBTS is already working with partners in different disease areas to address some of these policy issues. For example, at our recent Head to the Hill advocacy day, one of our asks of Congress was to support the Telehealth Modernization Act, legislation that would extend, expand and make permanent many of the policies that allowed telehealth to flourish during the COVID-19 pandemic. Similarly, policies should be put in place to ensure that disadvantaged patients have access to medical interpreters who can assist them in an era of increased telemedicine.
Issues specific to the brain tumor community
The brain tumor field will need to determine what specific aspects of brain tumor clinical trials (which may vary by type and phase of trial) need to be done at a central trial site versus what can be accomplished remotely or in the community provider setting. For aspects of trials that can be accomplished in a decentralized setting, to ensure rigor and reliability, it is important that the field:
The COVID-19 pandemic has created a major disruption in the traditional approach to brain tumor clinical trials, leading to enhanced regulatory and sponsor flexibility and the opportunity for innovation. Telehealth and telemedicine trends, emerging prior to the pandemic, have been exposed as new opportunities that can be carefully leveraged to improve the patient experience in the long term.
Titled, “Report of the National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from the COVID-19 Experience,” the paper explores the potential silver linings of the changes the pandemic has wrought, with Drs. Lee and Wen, Mr. Arons, and NBTS’s Research Program Administrator Clair Meehan among the authors.
NBTS thanks Drs. Lee, Wen, Amy Barone, Erik Bloomquist, Susan Chang, John de Groot, Eva Galanis, Islam Hassan, Chitkala Kalidas, Mustafa Khasraw, Mark Kieran, Joseph Kvedar, Andrew Lassman, Vinay Puduvalli, Solmaz Sahebjam, Lee Schwamm, Sharon Tamir, Mary Welch, Alfred Yung, and Gelareh Zadeh, for their support and partnership in shaping the meeting and subsequent paper, as well as Wendy Selig, Jeffrey Bacha, and Sharon Tamir.
For a more comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder, where you can search potential opportunities for enrollment based on criteria important and specific to you.
For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing firstname.lastname@example.org. Our patient navigator, Mary Lovely, PhD, RN, CNRN, has more than 30 years of experience working closely with brain tumor patients and families as a neurological nurse, clinical nurse specialist, and research nurse.
> Learn more